OxyContin wins 'abuse-deterrent' label, but FDA bans older generic forms
This article was originally published in Scrip
Executive Summary
Three years after the FDA OK'd Purdue Pharma's reformulated version of its controlled-release oxycodone drug, OxyContin, the company won the coveted "abuse-deterrent" language in the medicine’s labeling.
You may also be interested in...
If Egalet Wins At FDA, Arymo ER Still Might Not In Opioid Market
Potential sales impact of even broadest possible label for oral, intranasal and intravenous abuse remains a question mark given that abuse-deterrent products remain only a small percentage of market.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.